ArticleCase reports in otolaryngology2026
Peptide Receptor Radionucleotide Therapy for Unresectable Paediatric Head and Neck Paraganglioma in Aotearoa New Zealand.
Article in Case reports in otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck paragangliomas present incidentally or with signs of mass effect. Approximately 30%-40% are hereditary, which typically present at a younger age. Given their proximity to vital structures, they are often inoperable, and alternative treatment options have significant side effects. We present a case of a paediatric patient with a glomus jugulare paraganglioma who received peptide receptor radionucleotide therapy (PRRT), a targeted molecular therapy. We observed a good molecular response stable disease at 12-month follow-up and radiologically stable disease at 15 months posttreatment. PRRT is not currently a widely accessible treatment option, and the literature reports a reasonable disease response in treatment of head and neck paraganglioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.